-
Product Insights
Celiac Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Celiac Disease - Drugs In Development, 2023’, provides an overview of the Celiac Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Relapsing Remitting Multiple Sclerosis (RRMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Relapsing Remitting Multiple Sclerosis (RRMS) - Drugs In Development, 2023’, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KAN-101 in Celiac Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.KAN-101 in Celiac DiseaseDrug Details:KAN-101 is under development for the treatment of celiac disease. The drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YPEG-Somatropin in Idiopathic Short Stature
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.YPEG-Somatropin in Idiopathic Short Stature Drug Details:YPEG-somatropin is under development for the treatment of growth hormone...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ANK-700
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ANK-700 Drug Details ANK-700 is under development for the treatment of relapsing remitting multiple...
-
Product Insights
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – KAN-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry KAN-101 Drug Details KAN-101 is under development for the treatment of celiac disease. The...
-
Product Insights
Celiac Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Celiac Disease Drugs in Development Report Overview Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain, and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome, and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further, the treatment regime also involves adhering to a strict gluten-free diet. The Celiac Disease pipeline market report provides a comprehensive...